FeesSafety
Pluang+

Serve Robotics cuts 2026 revenue forecast drastically amid operational struggles and low robot use.

Market News
29 Oct 2026, 13:30 WIB
Seeking Alpha
View Source
Bearish
Serve Robotics cuts 2026 revenue forecast drastically amid operational struggles and low robot use.

Serve Robotics Inc. has sharply reduced its 2026 revenue guidance from $26 million to $9–$10 million due to operational challenges and poor utilization of its delivery robots, which are only used 40% of the time. The company now expects Q3 and Q4 revenues below $2 million, far short of earlier hopes exceeding $15 million. With high operating expenses of $140–$150 million and negative gross margins, Serve Robotics faces urgent pressure to increase revenue and improve its cost structure. The outlook remains uncertain until the company can demonstrate better execution and a clear path to profitability.

Serve Robotics' recent revenue challenges provide context for technology sector performance. For readers following technology stocks, here is Pluang's market snapshot as of Oct 29, 2026 15:51 WIB: out of 150 priced US tech stocks, 25 rose and 122 fell. Notable movers include FTNT at USD 130.00 with a 1-day change of -25.32%, NOW at USD 122.74 down 18.24%, and MRVL at USD 227.80 down 9.48%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App